The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 29 (2), 113-115
- https://doi.org/10.1038/sj.bmt.1703343
Abstract
The use of zanamivir in seven patients with influenza (three A and four B) post allograft is described. Inhaled zanamivir (10 mg twice daily) was continued from the diagnosis of influenza until excretion of virus ceased (median duration 15 days, range 5 to 44 days). There was no toxicity attributable to zanamivir and rapid resolution of influenza symptoms was seen. There was no mortality due to influenza in the seven patients. The good outcome of 30 previous patients with influenza post transplant is described. A randomised multicentre study would be required to demonstrate efficacy.Keywords
This publication has 6 references indexed in Scilit:
- Inhaled Zanamivir for the Prevention of Influenza in FamiliesNew England Journal of Medicine, 2000
- Respiratory Distress Associated with ZanamivirNew England Journal of Medicine, 2000
- The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantationBone Marrow Transplantation, 1999
- Infections in adults undergoing unrelated donor bone marrow transplantationBritish Journal of Haematology, 1999
- Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B VirusThe Journal of Infectious Diseases, 1998
- Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus InfectionsNew England Journal of Medicine, 1997